bluebird bio Inc (NASDAQ:BLUE) insider Nick Leschly sold 7,374 shares of the company’s stock in a transaction on Monday, January 7th. The stock was sold at an average price of $113.64, for a total value of $837,981.36. Following the sale, the insider now owns 20,682 shares of the company’s stock, valued at $2,350,302.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ BLUE opened at $116.89 on Friday. The firm has a market capitalization of $5.83 billion, a P/E ratio of -15.16 and a beta of 2.41. bluebird bio Inc has a twelve month low of $87.49 and a twelve month high of $236.17.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.90) by $0.17. The business had revenue of $11.50 million during the quarter, compared to the consensus estimate of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. bluebird bio’s quarterly revenue was up 49.2% on a year-over-year basis. During the same period in the prior year, the business posted ($1.73) earnings per share. Equities analysts anticipate that bluebird bio Inc will post -10.76 EPS for the current fiscal year.

Several brokerages have recently issued reports on BLUE. BidaskClub downgraded shares of bluebird bio from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 23rd. Oppenheimer reiterated a “hold” rating on shares of bluebird bio in a report on Tuesday, November 27th. Raymond James began coverage on shares of bluebird bio in a report on Wednesday, December 19th. They set a “strong-buy” rating and a $165.00 price target for the company. Goldman Sachs Group downgraded shares of bluebird bio from a “conviction-buy” rating to a “buy” rating in a report on Friday, September 21st. Finally, Morgan Stanley lowered their price target on shares of bluebird bio from $190.00 to $186.00 and set an “equal weight” rating for the company in a report on Monday, October 15th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $188.83.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Stratos Wealth Partners LTD. acquired a new stake in bluebird bio in the third quarter valued at $106,000. Belpointe Asset Management LLC acquired a new stake in bluebird bio in the third quarter valued at $110,000. NuWave Investment Management LLC increased its holdings in bluebird bio by 10,811.1% in the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 973 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its holdings in bluebird bio by 635.0% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock valued at $167,000 after purchasing an additional 997 shares during the period. Finally, Tower Research Capital LLC TRC acquired a new stake in bluebird bio in the second quarter valued at $201,000.

TRADEMARK VIOLATION NOTICE: “Nick Leschly Sells 7,374 Shares of bluebird bio Inc (BLUE) Stock” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://theolympiareport.com/2019/01/11/nick-leschly-sells-7374-shares-of-bluebird-bio-inc-blue-stock.html.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Recommended Story: The Structure of a Futures Contract

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.